Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean‐Charles Soria, Tony Mok, Yi‐Long Wu et al.|The Lancet Oncology|2015Cited by 412
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W. Riess, Helena A. Yu, Zofia Piotrowska et al.|JCO Precision Oncology|2025Cited by 10